Spring til hovednavigation Spring til søgning Spring til hovedindhold

Randomised controlled trial of two sequential artemisinin-based combination therapy regimens to treat uncomplicated falciparum malaria in African children: a protocol to investigate safety, efficacy and adherence

  • Henk Dfh Schallig
  • , Halidou Tinto
  • , Patrick Sawa
  • , Harparkash Kaur
  • , Stephan Duparc
  • , Deus S Ishengoma
  • , Pascal Magnussen
  • , Michael Alifrangis
  • , Colin J Sutherland
    27 Citationer (Scopus)

    Abstract

    BACKGROUND: Management of uncomplicatedPlasmodium falciparummalaria relies on artemisinin-based combination therapies (ACTs). These highly effective regimens have contributed to reductions in malaria morbidity and mortality. However, artemisinin resistance in Asia and changing parasite susceptibility to ACT in Africa have now been well documented. Strategies that retain current ACT as efficacious treatments are urgently needed.

    METHODS: We present an open-label, randomised three-arm clinical trial protocol in three African settings representative of varying malaria epidemiology to investigate whether prolonged ACT-based regimens using currently available formulations can eliminate potentially resistant parasites. The protocol investigates whether a sequential course of two licensed ACT in 1080 children aged 6-120 months exhibits superior efficacy against acuteP. falciparummalaria and non-inferior safety compared with standard single-course ACT given to 540 children. The primary endpoint is PCR-corrected clinical and parasitological response at day 42 or day 63 of follow-up. Persistence of PCR-detectable parasitaemia at day 3 is analysed as a key covariate. Secondary endpoints include gametocytaemia, occurrence of treatment-related adverse events in the double-ACT versus single-ACT arms, carriage of molecular markers of drug resistance, drug kinetics and patient adherence to treatment.

    DISCUSSION: This protocol addresses efficacy and safety of sequential ACT regimens inP. falciparummalaria in Africa. The approach is designed to extend the useful life of this class of antimalarials with maximal impact and minimal delay, by deploying licensed medicines that could be swiftly implemented as sequential double ACT by National Malaria Control Programmes, before emerging drug resistance in Africa becomes a major threat to public health.

    OriginalsprogEngelsk
    TidsskriftGlobal Health
    Vol/bind2
    Udgave nummer3
    Sider (fra-til)e000371
    ISSN2059-7908
    DOI
    StatusUdgivet - 30 aug. 2017

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Randomised controlled trial of two sequential artemisinin-based combination therapy regimens to treat uncomplicated falciparum malaria in African children: a protocol to investigate safety, efficacy and adherence'. Sammen danner de et unikt fingeraftryk.

    Citationsformater